Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeoGenomics's Ending Cash Position for the quarter that ended in Jun. 2026 was MXN2,540 Mil.
NeoGenomics's quarterly Ending Cash Position
declined
from Dec. 2025 (MXN2,874 Mil) to Mar. 2026 (MXN2,635 Mil) and
declined
from Mar. 2026 (MXN2,635 Mil) to Jun. 2026 (MXN2,540 Mil).
NeoGenomics's annual Ending Cash Position
increased
from Dec. 2023 (MXN5,813 Mil) to Dec. 2024 (MXN7,654 Mil) but then
declined
from Dec. 2024 (MXN7,654 Mil) to Dec. 2025 (MXN2,874 Mil).
The historical data trend for NeoGenomics's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
NeoGenomics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN2,540 Mil mean?
NeoGenomics (MEX:NEO) has a Ending Cash Position of MXN2,540 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Ending Cash Position too high?
NeoGenomics' current Ending Cash Position is MXN2,540 Mil. Overall, NeoGenomics has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Ending Cash Position compare to WGS and CDNA?
NeoGenomics' Ending Cash Position of MXN2,540 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on NeoGenomics and its competitors. NeoGenomics's current Ending Cash Position is MXN2,540 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
NeoGenomics (MEX:NEO) has a current Ending Cash Position of MXN2,540 Mil. The stock's GF Value™ is MXN179.30, compared to a current price of MXN176.40 — trading 1.6% below its estimated fair value. The current Ending Cash Position is MXN2,540 Mil. NeoGenomics' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Ending Cash Position is MXN2,540 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (MEX:NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued.
The current stock price of MXN176.40 is trading 1.6% below its estimated GF Value™ of MXN179.30.
Key valuation signals for MEX:NEO:
Ending Cash Position: MXN2,540 Mil
GF Value™: MXN179.30 vs. price of MXN176.40 (1.6% below fair value)
No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
69GF Score
Get the complete analysis for MEX:NEO
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NEO has been successfully added to your 
